Bioorganic & Medicinal Chemistry

# BIOORGANIC & MEDICINAL CHEMISTRY



# EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Bioorganic & Medicinal Chemistry 18 (2010) 2067–2075

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

# Bioorganic & Medicinal Chemistry Volume 18, Issue 6, 2010

# Contents

## ARTICLES






The crystal structures of the complexes of β-trypsin with *m*-guanidinosalicylidene-L-alaninato(aqua)copper(II) hydrochloride, [*N*,*N*′-bis(*m*-guanidinosalicylidene)ethylenediaminato]copper(II), and [*N*,*N*′-bis(*m*-amidinosalicylidene)ethylenediaminato]copper(II) have been determined. The structural and inhibitory activity data provide new avenues for designing novel inhibitors against physiologically important trypsin-like serine proteases.






**2, *k*i= 4.16 nM**

Synthesis of oligo(ethylene glycol)-alkene substituted the theophyllines (positions 7 and/or 8) is described. Compound **2** showed high affinity and selectivity for $A_{2B}$ receptor ($K_i$ = 4.16 nM, $K_{iA2A}/K_{iA2B}$ = 24.1). The alkenyl or azido substituents in some of the derivative allows for covalent attachment of them onto H-terminated silicon surfaces.






**17**

A series of novel 2′,5′-dimethoxylchalcone derivatives including 18 new compounds were synthesized and evaluated for cytotoxicities against two human cancer cell lines, NTUB1 (human bladder cancer cell line) and PC3 (human prostate cancer cell line) cell lines.




Two new alkyl 2,3-dihydroxybenzoates, gentisides A and B, were isolated from the traditional Chinese medicine *Gentiana rigescens* Franch. They showed a significant neuritogenic activity at 30 μM against PC12 cells that was comparable to that seen for the best nerve growth factor concentration of 40 ng/mL.






**8a** **8b**

We studied SAR and molecular mechanism of novel acylhydrazone compounds targeting HIV-1 CA. Among synthesized compounds, **8a** and **8b** possessed the most promising antiviral activities.





$IC_{50}$ = 5 μM $IC_{50}$ = 33 μM time dependent $IC_{50}$ = 41 μM





alstiphyllanine E alstiphyllanine F alstiphyllanine G alstiphyllanine H




Ki = 0.92 μM (hCA I); Ki = 0.87 μM (hCA II); Ki = 3.73 μM (hCA IX)











The isolation of acetylcholinesterase inhibitors ($IC_{50}$ = 9.7 μM) from fungal source is reported. The selective binding mode is resolved by docking studies. The pharmacological potential is further supported by Aβ-aggregation and cytotoxicity studies.






$IC_{50}$ (*h*SGLT2) = 7.03 nM

Novel C-aryl glucoside SGLT2 inhibitors containing 1,3,4-thiadiazole at the distal ring position were identified as potential antidiabetic agents. A selected compound demonstrated reasonable urinary glucose excretion and glucosuria in normal SD rats along with favorable blood glucose-lowering effects in db/db mice.













A number of 2-benzylidene-6-(nitrobenzylidene)cyclohexanones emerged as lead compounds which possess noteworthy cytotoxicity, selective toxicity towards neoplasms than non-malignant cells and well tolerated in mice in short-term toxicity studies.































*Stylophora pystillata* (coral) CA is activated by amines and amino acids.








The design, synthesis and biological evaluation of novel (*E*)-α-benzylthio chalcones as BCR-ABL kinase inhibitors are described. The structure–activity relationship, in vitro cytotoxicity in K562, a human leukemic cell line and inhibition of BCR-ABL phosphorylation by these compounds is discussed.











The methanolic extract from the whole plants of *Anastatica hierochuntica* was found to inhibit melanogenesis in theophylline-stimulated murine B16 melanoma 4A5 cells. Among the constituents isolated, anastatin A, silybin A, isosilybins A and B, several flavonoids, etc. inhibited the melanogenesis with $IC_{50}$ values of 6.1–32 μM. With regard to the mechanism of action of silybins and isosilybins, the inhibition of tyrosinase activity suggested to be important. In addition, isosilybins A and B inhibited the mRNA expression of TRP-2, but silybins A and B oppositely enhanced the mRNA expression of tyrosinase, TRP-1 and -2 at 10 and/or 30 μM, and the inhibition of phosphorylation of extracellular signal-regulated kinases (ERK1/2) is involved in the enhanced expression of mRNA, at least in part.

## OTHER CONTENTS



*Corresponding author
Supplementary data available via ScienceDirect

## COVER

An insight into biologically relevant chemical space showing the scaffolds of potential natural-product based inhibitors orbiting their target, the protein structure of protein 11-beta steroid dehydrogenase (PDB code 1xu7). Graphic produced using Pymol (http://www.pymol.org). [M. A. Koch, A. Schuffenhauer, M. Scheck, S. Wetzel, M. Casaulta, A. Odermatt, P. Ertl, H. Waldmann, Charting biologically relevant chemical space: A structural classification of natural products (SCONP), *PNAS* **2005**, *102*, 17272–17277 and S. Wetzel, H. Waldmann, Cheminformatic analysis of natural products and their chemical space, *Chimia* **2007**, *61*(6), 355–360].



Indexed/Abstracted in: Beilstein, Biochemistry & Biophysics Citation Index, CANCERLIT, Chemical Abstracts, Chemistry Citation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica, MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®

ELSEVIER

ISSN 0968-0896

Bioorganic & Medicinal Chemistry 18 (2010) 2152–2158

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

# Alstiphyllanines E–H, picraline and ajmaline-type alkaloids from *Alstonia macrophylla* inhibiting sodium glucose cotransporter

Hiroko Arai [a], Yusuke Hirasawa [a], Abdul Rahman [b], Idha Kusumawati [b], Noor Cholies Zaini [b], Seizo Sato [c], Chihiro Aoyama [c], Jiro Takeo [c], Hiroshi Morita [a,*]

[a] Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142-8501, Japan
[b] Faculty of Pharmacy, Airlangga University, Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia
[c] Central Research Laboratory, Nippon Suisan Kaisha, Ltd, 559-6 Kitano-machi, Hachioji, Tokyo 192-0906, Japan

ARTICLE INFO

*Article history:*
Received 10 December 2009
Revised 29 January 2010
Accepted 30 January 2010
Available online 6 February 2010

*Keywords:*
Indole alkaloids
*Alstonia macrophylla*
Alstiphyllanines E–H
SGLT

ABSTRACT

Three new picraline-type alkaloids, alstiphyllanines E–G (**1**–**3**) and a new ajmaline-type alkaloid, alstiphyllanine H (**4**) were isolated from the leaves of *Alstonia macrophylla* together with 16 related alkaloids (**5**–**20**). Structures and stereochemistry of **1**–**4** were fully elucidated and characterized by 2D NMR analysis. Alstiphyllanines E and F (**1** and **2**) showed moderate $Na^+$-glucose cotransporter (SGLT1 and SGLT2) inhibitory activity. A series of a hydroxy substituted derivatives **21**–**28** at C-17 of the picraline-type alkaloids have been derived as having potent SGLT inhibitory activity. 10-Methoxy-*N*(1)-methylburnamine-17-*O*-veratrate (**6**) exhibited potent inhibitory activity, suggesting that the presence of an ester side chain at C-17 may be important to show SGLT inhibitory activity. Structure activity relationship of alstiphyllanines on inhibitory activity of SGLT was discussed.



## 1. Introduction

$Na^+$-glucose cotransporter (SGLT) is a membrane protein that plays an important role in the re-absorption of glucose in the kidneys. SGLT is known to have three isoforms (SGLT1, SGLT2, and SGLT3).[1–3] SGLT1 is expressed primarily in the brush border membrane of mature enterocytes in the small intestine, where it absorbs dietary glucose and galactose from the gut lumen.[4] SGLT2 is only expressed in the renal cortex, where it is assumed to be present in the brush border membrane of the S1 and S2 segments of the proximal tubule, and to be responsible for the re-absorption of glucose from the glomerular filtrate.[4] It is expected that the inhibition of SGLT could decrease glucose re-absorption and that this could thus result in an increase in urinary sugar excretion, and a decrease in blood glucose level. Thus, SGLT inhibitors have therapeutic potential for type 2 diabetes.[5]

Our screening study on SGLT inhibitors in traditional medicine[6] discovered that the methanol extract of *Alstonia macrophylla* shows moderate SGLT inhibitory activity. The genus *Alstonia*, which is widely distributed in tropical regions of Africa and Asia, are well-known rich sources of unique monoterpene indole alkaloids with various biological activities such as anticancer, antibacterial, anti-inflammatory, antitussive, and antimalarial properties.[7] Recently, several new indole alkaloids were isolated from extracts of *Alstonia*



1



2



3



4

* Corresponding author. Tel./fax: +81 3 5498 5778.
*E-mail address:* moritah@hoshi.ac.jp (H. Morita).

0968-0896/$ - see front matter © 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2010.01.077

species collected in Indonesia and Malaysia.[8,9] With an aim to isolate additional alkaloids against SGLT inhibitory activity, purification of extracts of *A. macrophylla* Wall.ex G. Don (Apocynaceae) collected in Indonesia led to four new alkaloids alstiphyllanines E–H (**1**–**4**) together with 16 known alkaloids (**5**–**20**). Herein we report the isolation and structure elucidation of four new indole alkaloids, alstiphyllanines E–H (**1**–**4**) from *A. macrophylla* as well as SGLT inhibitory activity and structure activity relationship (SAR) study of some picraline-type indole alkaloids.

## 2. Results and discussion

### 2.1. Structures of alstiphyllanines E–H (1–4)

Leaves of *A. macrophylla* were extracted with MeOH, and the extract was partitioned between EtOAc and 3% aqueous tartaric acid. Water-soluble materials, adjusted to pH 9 with satd aq $Na_2CO_3$, were extracted with $CHCl_3$. The $CHCl_3$-soluble materials were subjected to an LH-20 column ($CHCl_3$/MeOH, 1:1) followed by a silica gel column ($CHCl_3$/MeOH, 1:0–0:1). The eluted fractions were further separated by ODS HPLC (MeOH/$H_2O$/TFA) to afford **1** (1.8 mg, 0.00050% dry weight), **2** (1.3 mg, 0.00036%), **3** (10.4 mg, 0.0029%), and **4** (3.6 mg, 0.0013%), together with 16 known alkaloids, burnamine-17-*O*-3′,4′,5′-trimethoxybenzoate[10] (**5**), 10-methoxy-*N*(1)-methylburnamine-17-*O*-veratrate[10] (**6**), alstiphyllanine D[9] (**7**), alstiphyllanine B[9] (**8**), alstiphyllanine C[9] (**9**), picralinal[11] (**10**), picrinine[11] (**11**), quaternine[12] (**12**), *O*-deacetylpicraline[13] (**13**), vincamedine[14] (**14**), vincamajine[15] (**15**), alstiphyllanine A[9] (**16**), vincamajine-17-*O*-veratrate[16] (**17**), vincamajine-17-*O*-3′,4′,5′-trimethoxybenzoate[16] (**18**), alstonal[17] (**19**), and alstonerine[14] (**20**).

Alstiphyllanine E {**1**, $[\alpha]_D^{26}$ −93 (*c* 1.0, MeOH)} was revealed to have the molecular formula $C_{30}H_{32}N_2O_7$, by HRESITOFMS [*m*/*z* 533.2272 $(M+H)^+$, $\Delta$ −1.6 mmu]. The $^1$H NMR data (Table 1) showed the presence of seven aromatic protons, an ethylidene side chain, a methyl ester function, and two methoxy groups. The HMBC cross-peak of $H_2$-21 to C-19 indicated the ethylidene side chain at C-20. The position of each methoxy group was confirmed by HMBC correlations of *O*-Me to C-3′ and C-4′. HMBC correlations for H-5 to C-2, $H_2$-17 to C-7, and $H_2$-6 to C-16 indicated alstiphyllanine E possessed picraline-type skeleton. The molecular formulae of alstiphyllanine E was smaller than that of burnamin-17-*O*-3′,4′,5′-trimethoxybenzoate[9] by $CH_2O$ unit. Compared with $^1$H NMR data of burnamin-17-*O*-3′,4′,5′-trimethoxybenzoate,[9] alstiphyllanine E was suggested a picraline-type backbone without *O*-Me at C-5′. The relative stereochemistry of **1** was elucidated by NOESY correlations as shown in computer-generated 3D drawing (Fig. 1). The NOESY correlation of $H_3$-18 to H-15 indicated that the geometry of ethylidene side chain was *E*. The β-orientation of C-17 was elucidated by the NOESY correlation of H-14b/H-17a.

Alstiphyllanine F {**2**, $[\alpha]_D^{26}$ −32 (*c* 1.0, MeOH)} was revealed to have the molecular formula $C_{32}H_{36}N_2O_9$, by HRESITOFMS [*m*/*z* 593.2511 $(M+H)^+$, $\Delta$ −1.2 mmu], which was larger than that of burnamin-17-*O*-3′,4′,5′-trimethoxybenzoate by $CH_2O$ unit. Compared with $^1$H NMR data of burnamin-17-*O*-3′,4′,5′-trimethoxybenzoate, alstiphyllanine F was suggested a picraline-type backbone with *O*-Me. The HMBC cross-peak of $H_3$-*O*-Me ($\delta_H$ 3.27) to C-10 ($\delta_C$ 156.5) revealed the presence of an indole moiety with a methoxy group at C-10. HRESITOFMS data [*m*/*z* 413.2080 $(M+H)^+$, $\Delta$ −0.4 mmu] of alstiphyllanine G {**3**, $[\alpha]_D^{26}$ −42 (*c* 1.0, MeOH)} established the molecular formula, $C_{23}H_{28}N_2O_5$, which was larger than that of *O*-deacetylpicraline[13] by $C_2H_4O$ unit. The NMR data of **3** were analogous to those of *O*-deacetylpicraline[13] except for the following observation: a methoxy signal ($\delta_H$ 3.70) and an *N*-methyl signal ($\delta_H$ 2.89) lacking in *O*-deacetylpicraline appeared for **3**. The presence of both methyl groups was verified by the HMBC correlations of the methoxy protons to C-10 and the *N*-methyl protons to C-2 and C-13.

Alstiphyllanine H {**4**, $[\alpha]_D^{26}$ −21 (*c* 1.0, MeOH)} was obtained as a brown amorphous solid and was revealed to have the molecular formula $C_{22}H_{26}N_2O_4$, by HRESITOFMS [*m*/*z* 383.1971 $(M+H)^+$, $\Delta$ −2.7 mmu], which was larger than that of vincamajine[15] by an oxygen unit. The $^1$H NMR data (Table 1) showed the presence of four aromatic protons, an ethylidene side chain, a methyl ester function, and an *N*-methyl group. Partial structures C-9–C-12,

**Table 1**
$^1$H NMR data [$\delta_H$ (*J*, Hz)] of alstiphyllanines E-H (**1**–**4**)

| | **1**[a] | **2**[a] | **3**[b] | **4**[a] |
|---|---|---|---|---|
| 2 | | | | 3.55 (d, 4.8) |
| 3 | 4.07 (s) | 4.00 (s) | 3.73 (d, 3.6) | 4.39 (m) |
| 5 | 5.56 (s) | 5.56 (s) | 4.72 (d, 2.6) | 4.42 (m) |
| 6a | 2.67 (d, 15.4) | 2.66 (15.1) | 2.33 (dd, 13.9, 2.6) | 2.53 (d, 14.4) |
| 6b | 3.17 (d, 15.4) | 3.25 (m) | 3.30 (d, 13.9) | 2.73 (d, 14.4) |
| 9 | 7.56 (d, 7.4) | 7.03 (s) | 6.93 (d, 2.6) | 7.20 (d, 7.2) |
| 10 | 6.54 (dd, 7.4, 7.2) | | | 6.83 (dd, 7.2, 7.2) |
| 11 | 6.87 (dd, 7.5, 7.2) | 6.60 (d, 8.4) | 6.73 (dd, 8.5, 2.6) | 7.19 (dd, 7.6, 7.2) |
| 12 | 6.73 (d, 7.5) | 6.33 (d, 8.4) | 6.59 (d, 8.5) | 6.77 (d, 7.6) |
| 14a | 2.23 (d, 14.8) | 2.29 (d, 15.1) | 1.97 (m) | 2.10 (m) |
| 14b | 2.41 (d, 14.8) | 2.37 (d, 15.1) | | 2.74 (m) |
| 15 | 3.40 (s) | 3.35 (s) | 3.48 (s) | 3.36 (s) |
| 17a | 4.08 (d, 11.4) | 4.09 (d, 10.9) | 3.47 (d, 12.3) | 4.16 (s) |
| 17b | 4.57 (d, 11.4) | 4.94 (d, 10.9) | 3.73 (d, 12.3) | |
| 18 | 1.70 (d, 6.8) | 1.76 (d, 7.2) | 1.56 (dd, 7.1, 2.0) | 1.61 (d, 6.5) |
| 19 | 5.74 (q, 6.8) | 5.76 (q, 7.2) | 5.35 (q, 7.1) | 5.55 (q, 6.5) |
| 21a | 4.25 (d, 17.1) | 4.02 (m) | 3.11 (d, 15.9) | 4.46 (d, 15.1) |
| 21b | 4.00 (d, 17.1) | 4.16 (d, 16.1) | 3.66 (d, 15.9) | 4.55 (d, 15.1) |
| $CO_2Me$ | 3.75 (s) | 3.80 (s) | 3.72 (s) | 3.73 (s) |
| 10-*O*-*Me* | | 3.27 (s) | 3.70 (s) | |
| 3′-*O*-*Me* | 3.86 (s) | 3.89 (s) | | |
| 4′-*O*-*Me* | 3.88 (s) | 3.81 (s) | | |
| 5′-*O*-*Me* | | 3.89 (s) | | |
| *N*(1)-*Me* | | | 2.89 (s) | 2.66 (s) |
| 2′ | 7.15 (s) | 6.91 (s) | | |
| 5′ | 6.94 (d, 8.4) | | | |
| 6′ | 7.28 (d, 8.4) | 6.91 (s) | | |

[a] TFA salt in $CD_3OD$.
[b] Free base in $CDCl_3$.




**Figure 1.** Selected 2D NMR correlations for alstiphyllanine E (**1**).

C-5–C-6, C-2–C-15, and C-18–C-19 were deduced from a detailed analysis of $^{1}H$-$^{1}H$ COSY spectrum of **4**. The HMBC cross-peaks of $H_3$-18 to C-20 and H-19 to C-15 indicated the presence of an ethylidene side chain at C-20 (Fig. 2). And the presence of an indoline ring was elucidated by HMBC correlations for H-9 to C-7 and *N*-Me to C-2 and C-13. HMBC correlations for H-2, H-5, and H-6a to C-17 and H-6a and H-14a to C-16 indicated alstiphyllanine H possessed ajmaline-type skeleton. Comparison of $^{13}C$ chemical shifts of C-3, C-5, and C-21 ($\delta_C$ 70.5, 77.4, and 67.3, respectively) in **4** with those ($\delta_C$ 53.2, 61.7, and 55.6, respectively) of vincamedine[14] indicated the presence of an *N*-oxide functionality at *N*-4. The relative stereochemistry of **4** was elucidated by NOESY correlations as shown in computer-generated 3D drawing (Fig. 2). NOESY correlations of $H_3$-18 to H-21 indicated that the geometry of the ethylidene side chain was *Z*. The NOESY correlations of H-3/H-2 and H-14a and H-14b/H-17 indicated that H-2 was α-orientated and H-17 was β-oriented. Oxidation of vincamajine with *m*-chloroperoxybenzoic acid (*m*-CPBA) afforded the *N*-oxide derivative, whose spectral data and the $[\alpha]_D$ value were identical with those of natural alstiphyllanine H. Thus, the structure of asltiphyllanine H was elucidated as shown in Figure 2.

**Table 2**
$^{13}C$ NMR data ($\delta_C$) of alstiphyllanines E–H (**1**–**4**)

| | **1**[a] | **2**[a] | **3**[b] | **4**[a] |
|---|---|---|---|---|
| 2 | 109.5 | 106.6 | 109.6 | 70.9 |
| 3 | 54.8 | 53.3 | 49.4 | 70.5 |
| 5 | 90.5 | 89.9 | 86.9 | 77.4 |
| 6 | 41.6 | 44.6 | 44.8 | 32.1 |
| 7 | 53.1 | 53.1 | 52.7 | 57.3 |
| 8 | 132.9 | 136.0 | 134.2 | 130.1 |
| 9 | 128.4 | 117.4 | 113.3 | 126.4 |
| 10 | 122.4 | 156.5 | 154.5 | 120.9 |
| 11 | 129.6 | 112.9 | 112.9 | 129.7 |
| 12 | 112.1 | 112.8 | 109.5 | 110.7 |
| 13 | 149.4 | 143.8 | 145.4 | 155.2 |
| 14 | 20.4 | 22.5 | 21.6 | 22.9 |
| 15 | 39.9 | 37.0 | 33.0 | 36.3 |
| 16 | 59.0 | 58.5 | 57.5 | 63.3 |
| 17 | 67.3 | 69.6 | 64.1 | 74.6 |
| 18 | 13.1 | 14.7 | 13.1 | 12.8 |
| 19 | 128.2 | 126.0 | 119.9 | 122.1 |
| 20 | 132.9 | 132.5 | 137.8 | 129.5 |
| 21 | 42.2 | 47.2 | 46.7 | 67.3 |
| 22 | 172.8 | 174.8 | 174.6 | 171.3 |
| 23 | 166.3 | 166.5 | | |
| $CO_2Me$ | 52.4 | 53.1 | 55.8 | 52.9 |
| 10-*O*-*Me* | | 56.2 | 51.8 | |
| 3′-*O*-*Me* | 56.4 | 57.3 | | |
| 4′-*O*-*Me* | 56.4 | 61.8 | | |
| 5′-*O*-*Me* | | 57.3 | | |
| *N*(1)-*Me* | | | 30.1 | 35.0 |
| 1′ | 122.5 | 125.8 | | |
| 2′ | 129.6 | 108.7 | | |
| 3′ | 149.8 | 154.9 | | |
| 4′ | 153.1 | 143.9 | | |
| 5′ | 111.6 | 154.9 | | |
| 6′ | 125.0 | 108.7 | | |

[a] TFA salt in $CD_3OD$.
[b] Free base in $CDCl_3$.

## 2.2. SGLT inhibitory activity

The in vitro SGLT inhibitory potential of alkaloids **1**–**20** was assessed by monitoring inhibition of uptaking of methyl-α-D-glucopyranoside in cultured cells expressing SGLT1 or SGLT2 at 50 μM (Table 3). As shown in Table 3, picraline-type alkaloids with veratrate or trimethoxybenzoate at C-17 such as compounds **1**, **2**, and **5**–**7**, showed inhibitory activity against SGLT1 and SGLT2. However, compounds **8** and **9** which have an *N*(4)-Me group were found to have no SGLT inhibitory activity. Any ajmaline and macroline type alkaloids (**4** and **14**–**20**) did not show inhibition on SGLT1 and SGLT2.

To discuss SAR of picraline-type alkaloids showing SGLT inhibitory activity, we prepared eight picraline-type derivatives **21**–**28** from **6** and **7** by use of acyl anhydride, *m*-CPBA, and boron tribromide, respectively (Table 4). As shown in Table 4, the presence of an *N*(1)-Me group promoted SGLT1 inhibitory activity when compared to those of **1**, **2** and **5**. Compound **22** which was converted a methoxy group at C-10 of **7** into a hydroxyl showed less activity against SGLT1, whereas *N*(4)-oxide derivatives **23** and **24** with a




**Figure 2.** Selected 2D NMR correlations for alstiphyllanine H (**4**).

**Table 3**
Structures and SGLT inhibitory activity of alkaloids **1–20**

| | $R^1$ | $R^2$ | $R^3$ | $R^4$ | | Inhibition %[a] | |
|---|---|---|---|---|---|---|---|
| | | | | | | SGLT1 | SGLT2 |
| *Picraline-type alkaloids* | | | | | | | |
| **1** | $CH_2O$-Bz$(OMe)_2$ | H | H | H | | 60.3 | 85.9 |
| **2** | $CH_2O$-Bz$(OMe)_3$ | OMe | H | H | | 65.2 | 103.8 |
| **3** | $CH_2OH$ | OMe | Me | H | | 14.0 | 31.6 |
| **5** | $CH_2O$-Bz$(OMe)_3$ | H | H | H | 19*Z* | 53.0 | 87.3 |
| **6** | $CH_2O$-Bz$(OMe)_2$ | OMe | Me | H | | 95.8 | 102.6 |
| **7** | $CH_2O$-Bz$(OMe)_3$ | OMe | Me | H | | 89.9 | 101.4 |
| **8** | $CH_2O$-Bz$(OMe)_2$ | OMe | Me | H | *N*(4)-Me | -10.3 | -0.2 |
| **9** | $CH_2O$-Bz$(OMe)_3$ | OMe | Me | H | *N*(4)-Me | -8.2 | -6.1 |
| **10** | CHO | H | H | H | | 16.5 | 36.3 |
| **11** | H | H | H | H | | 9.6 | 27.3 |
| **12** | H | OMe | H | OMe | | 11.7 | 30.0 |
| **13** | $CH_2OH$ | H | H | H | | 10.1 | -0.2 |
| *Ajmaline-type alkaloids* | | | | | | | |
| **4** | Me | OH | | | *N*(4)-oxide | 4.3 | 23.1 |
| **14** | Me | OAc | | | | 22.0 | 47.4 |
| **15** | Me | OH | | | | 11.5 | 30.6 |
| **16** | Me | OAc | | | *N*(4)-oxide | 5.3 | 38.5 |
| **17** | Me | OBz$(OMe)_2$ | | | | 26.0 | 44.0 |
| **18** | Me | OBz$(OMe)_3$ | | | | 7.2 | 47.6 |
| *Macroline-type alkaloids* | | | | | | | |
| **19** | | | | | | 15.8 | 26.8 |
| **20** | | | | | | 20.7 | 27.7 |



picraline type
(**1**-**3** and **5**-**13**)



ajmaline type
(**4** and **14**-**18**)



macroline type
**19**



macroline type
**20**

[a] Inhibition (%) at 50 μM.

**Table 4**
Structures and SGLT inhibitory activity of picraline-type derivatives **1**, **2**, **5–7**, and **21–28**

| | $R^1$ | $R^2$ | $R^3$ | | Inhibition %[a] ($IC_{50}$ μM) | |
|---|---|---|---|---|---|---|
| | | | | | SGLT1 | SGLT2 |
| **1** | $CH_2O$-Bz$(OMe)_2$ | H | H | | 60.3 (44) | 85.9 (40) |
| **2** | $CH_2O$-Bz$(OMe)_3$ | OMe | H | | 65.2 (39) | 103.8 (40) |
| **5** | $CH_2O$-Bz$(OMe)_3$ | H | H | 19*Z* | 53.0 (50) | 87.3 (35) |
| **6** | $CH_2O$-Bz$(OMe)_2$ | OMe | Me | | 95.8 (4) | 102.6 (0.5) |
| **7** | $CH_2O$-Bz$(OMe)_3$ | OMe | Me | | 89.9 (5) | 101.4 (2) |
| **21** | $CH_2O$-Bz | OMe | Me | | 85.2 (17) | 100.1 (1) |
| **22** | $CH_2O$-Bz$(OH)_3$ | OH | Me | | 46.9 (50) | 95.6 (7) |
| **23** | $CH_2O$-Bz$(OMe)_2$ | OMe | Me | *N*(4)-oxide | 94.6 (5) | 64.9 (35) |
| **24** | $CH_2O$-Bz$(OMe)_3$ | OMe | Me | *N*(4)-oxide | 93.8 (4) | 91.4 (11) |
| **25** | $CH_2O$-cinnamoyl | OMe | Me | | 96.3 (5) | 102.8 (1) |
| **26** | $CH_2O$-Ac | OMe | Me | | 5.4 (>100) | 39.9 (78) |
| **27** | $CH_2OCOCH_2CH_3$ | OMe | Me | | 27.1 (97) | 86.9 (12) |
| **28** | $CH_2O$-Bn | OMe | Me | | 7.6 (>100) | 25.7 (>100) |



picraline type (**1**, **2**, **5**-**7**, and **21**-**28**)

[a] Inhibition (%) at 50 μM.

methoxy group at C-10 showed less activity against SGLT2. Aliphatic esters at C-17 such as **26** and **27** showed less activity against both SGLT1 and SGLT2, and the presence of an aromatic long side chain at C-17 such as cinnamoyl derivative **25** potentiated the inhibitory activity against SGLT1 and SGLT2. On the other hand, the benzyl ether derivative **28** at C-17 did not show inhibitory activity.

In this work, three new picraline-type alkaloids, alstiphyllanines E–G (**1–3**) and a new ajmaline-type alkaloid, alstiphyllanine H (**4**) were isolated from the leaves of *A. macrophylla*, and their

structures were fully elucidated by 2D NMR analysis. SAR study of these alkaloids and synthetic analogue against STLT1 and SGLT2 suggested that the presence of picraline-type alkaloid with an ester side chain at C-17 may be important to show inhibitory activity.

## 3. Experimental section

### 3.1. General methods

$^1$H and 2D NMR spectra were recorded on a Bruker AV 400 spectrometer and chemical shifts were reported using residual $CD_3OD$ ($\delta_H$ 3.31 and $\delta_C$ 49.0) as internal standards. Standard pulse sequences were employed for the 2D NMR experiments. $^1$H–$^1$H COSY, HOHAHA, and NOESY spectra were measured with spectral widths of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 $t_1$ increments. NOESY spectra in the phase sensitive mode were measured with a mixing time of 800 ms. For HMQC spectra in the phase sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1 K for $F_1$ and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

### 3.2. Material

The leaves of *A. macrophylla* were collected at Purwodadi Botanical Garden, Indonesia in 2006. The botanical identification was made by Ms. Sri Wuryanti, Purwodadi Botanical Garden, Indonesia. A voucher specimen has been deposited in the herbarium at Purwodadi Botanical Garden, Pasuruan, Indonesia.

### 3.3. Extraction and isolation

The leaves of *A. macrophylla* (363.5 g) were extracted with MeOH. The MeOH extract (43.8 g) was treated with 3% tartaric acid (pH 2) and then partitioned with EtOAc. The aqueous layer was treated with satd aq $Na_2CO_3$ aq to pH 9 and extracted with $CHCl_3$ to give alkaloidal fraction (2.06 g). The alkaloidal fraction was purified by LH-20 column ($CHCl_3$/MeOH, 1:0) and $SiO_2$ column ($CHCl_3$/MeOH, 1:0→0:1) and the fraction eluted by MeOH was purified by ODS HPLC ($CH_3CN/H_2O/CF_3CO_2H$, 45:55:0.1; flow rate, 2 mL/min; UV detection at 254 nm) to afford alstiphyllanines E (**1**, 1.8 mg, 0.00050% yield), F (**2**, 1.3 mg, 0.00036%), G (**3**, 10.4 mg, 0.0029%), and H (**4**, 3.6 mg, 0.0013%), together with known alkaloids, burnamine-17-*O*-3′,4′,5′-trimethoxybenzoate[10] (**5**), 10-methoxy-*N*(1)-methylburnamine-17-*O*-veratrate[10] (**6**), alstiphyllanine D[9] (**7**), alstiphyllanine B[9] (**8**), alstiphyllanine C[9] (**9**), picralina[11] (**10**), picrinine[11] (**11**), quaternine[12] (**12**), *O*-deacetylpicraline[13] (**13**), vincamedine[14] (**14**), vincamajine[15] (**15**), alstiphyllanine A[9] (**16**), vincamajine-17-*O*-veratrate[16] (**17**), vincamajine-17-*O*-3′,4′,5′-trimethoxybenzoate[16] (**18**), alstonal[17] (**19**), alstonerine[14] (**20**).

#### 3.3.1. Alstiphyllanine E (1)

Brown amorphous solid; $[\alpha]_D^{26}$ −93 (*c* 1.0, MeOH); IR (film) $\nu_{max}$ 3390, 1740, and 1680 cm$^{-1}$; UV (MeOH) $\lambda_{max}$ 291 (ε 4700), 264 (6200), and 204 (27,000) nm; $^1$H and $^{13}$C NMR data (Tables 1 and 2); ESIMS *m*/*z* 533 (M+H)$^+$; HRESITOFMS *m*/*z* 533.2272 [(M+H)$^+$, Δ −1.6 mmu, calcd for $C_{30}H_{33}N_2O_7$, 533.2288].

#### 3.3.2. Alstiphyllanine F (2)

Brown amorphous solid; $[\alpha]_D^{26}$ −32 (*c* 1.0, MeOH); IR (film) $\nu_{max}$ 3420, 1740, and 1680 cm$^{-1}$; UV (MeOH) $\lambda_{max}$ 245 (ε 6800) and 204 (28,000) nm; $^1$H and $^{13}$C NMR data (Tables 1 and 2); ESIMS *m*/*z* 593 (M+H)$^+$; HRESITOFMS *m*/*z* 593.2511 [(M+H)$^+$, Δ +1.2 mmu, calcd for $C_{32}H_{37}N_2O_9$, 593.2499].

#### 3.3.3. Alstiphyllanine G (3)

Brown amorphous solid; $[\alpha]_D^{26}$ −42 (*c* 1.0, MeOH); IR (film) $\nu_{max}$ 3420 and 1720 cm$^{-1}$; UV (MeOH) $\lambda_{max}$ 306 (ε 1500), 240 (3500), and 204 (12,000) nm; $^1$H and $^{13}$C NMR data (Tables 1 and 2); ESIMS *m*/*z* 413 (M+H)$^+$; HRESITOFMS *m*/*z* 413.2080 [(M+H)$^+$, Δ +0.4 mmu, calcd for $C_{23}H_{28}N_2O_5$, 413.2076].

#### 3.3.4. Alstiphyllanine H (4)

Brown amorphous solid; $[\alpha]_D^{26}$ −21 (*c* 1.0, MeOH); IR (film) $\nu_{max}$ 3420 and 1740 cm$^{-1}$; UV (MeOH) $\lambda_{max}$ 291 (ε 1400) and 204 (10,000) nm; $^1$H and $^{13}$C NMR data (Tables 1 and 2); ESIMS *m*/*z* 383 (M+H)$^+$; HRESITOFMS *m*/*z* 383.1944 [(M+H)$^+$, Δ −2.7 mmu, calcd for $C_{22}H_{26}N_2O_4$, 383.1971].

#### 3.3.5. Conversion of vincamajine (15) to alstiphyllanine H (4)

*m*-Chloroperoxybenzoic acid (0.9 mg) was added to a stirred solution of vincamajine (**15**, 0.9 mg) in $CH_2Cl_2$ (0.2 mL) at room temperature. The mixture was stirred at 0 °C for 10 min, and washed with 20% $Na_2SO_2$ (5 mL) and $H_2O$ (5 mL), and concentrated to give a pale yellow solid. The residue was subjected to a silica gel column ($CHCl_3$/MeOH, 10:1) to give the N-oxide derivative (1.5 mg), whose spectral data and $[\alpha]_D$ value were identical with those of alstiphyllanine H (**4**).

#### 3.3.6. Conversion of 6 to 3

A mixture of 39.6 mg of alkaloid **6** and 20 mL of 5% NaOMe were heated for 30 min under stirring. The solution was diluted with water and extracted with $CHCl_3$. The extract was treated with 3% tartaric acid (pH 2) and then partitioned with EtOAc. The aqueous layer was treated with saturated $Na_2CO_3$ aq to pH 9 and extracted with $CHCl_3$ to give **3** (27.1 mg, 95.8%).

#### 3.3.7. Conversion of 3 to Its benzoate derivative (21)

To a solution of **3** (3.2 mg) in $CH_2Cl_2$ (0.1 mL) was added benzoic anhydride (4.5 mg) and DMAP (3.2 mg), and the solution was stirred at room temperature. The mixture was diluted with $CHCl_3$ and washed with water, satd aq $NaHCO_3$, and water. The organic phase was dried over $MgSO_4$ and concentrated in vacuo, and then purified by an ODS HPLC (MeOH/$H_2O$/formic acid; flow rate, 2 mL/min; UV detection at 254 nm) to obtain **21** (2.4 mg, 60.0%): $[\alpha]_D^{27}$ −38 (*c* 0.1, MeOH); IR (film) 1740 and 1710 cm$^{-1}$; $^1$H NMR ($CD_3OD$) δ 7.61 (dd, 7.6, 7.6, H-2′, 6′), 7.55 (dd, 7.6, 7.6, H-4′), 7.39 (d, 7.6, H-3′, 5′), 7.05 (d, 2.5, H-9), 6.57 (d, 8.6, H-12), 6.42 (dd, 2.5, 8.6, H-11), 5.66 (q, 6.9, H-19), 5.49 (br s, H-5), 4.78 (d, 10.9, H-17), 4.24 (d, 10.9, H-17) 4.12 (m, H-21), 3.70 (s, –OMe), 3.64 (br s, H-3, 15), 3.41 (s, –OMe), 3.35 (d, 15.0, H-6), 2.94 (s, –NMe), 2.53 (d, 15.0, H-6), 2.29 (d, 15.1, H-14), 2.19 (d, 15.1, H-14), 1.70 (d, 6.92, H-18); HRESIMS *m*/*z* 517.2323 [calcd for $C_{30}H_{33}N_2O_6$ (M+H)$^+$, 517.2339].

#### 3.3.8. Conversion of 7 to its hydroxy derivative (22)

A solution of boron tribromide in $CH_2Cl_2$ (1.0 M, 8.1 μL) was added dropwise to stirred solution of **7** (1.1 mg) in $CH_2Cl_2$ (50 μL), stirring being continued for 15 min at 0 °C. The reaction mixture was quenched with water and diluted with EtOAc. The organic layer was successively washed with water and brine, dried with $MgSO_4$, and concentrated in vacuo. The residue was chromatographed on an ODS HPLC (MeOH/$H_2O$/formic acid, 55:45:0.1; flow rate, 2 mL/min; UV detection at 254 nm) to give compound **22** (0.3 mg, 30.3 %): $[\alpha]_D^{27}$ −78 (*c* 0.1, MeOH); IR (film) 3420, 1740, and 1710 cm$^{-1}$; $^1$H NMR ($CD_3OD$) δ 7.00 (d, 8.4, H-9), 6.87 (s, H-2′, 6′), 6.58 (d, 2.5, H-12), 6.51 (dd, 8.4, 2.5, H-11), 5.74 (q, 7.7, H-19), 5.41 (br s, H-5), 4.53 (d, 11.4, H-17), 4.25 (d,

11.4, H-17), 4.19 (br s, H-3), 3.72 (br s, H-15), 3.99 (m, H-21), 3.70 (s, –OMe), 3.30 (m, H-6), 2.95 (s, –NMe), 2.60 (d, 15.9, H-6), 2.34 (d, 16.1, H-14), 2.28 (d, 16.1, H-14), 1.72 (d, 7.7, H-18); HRESIMS *m*/*z* 551.2052 [calcd for $C_{29}H_{31}N_2O_9(M+H)^+$, 551.2030].

### 3.3.9. Conversion of 6 to Its *N*(4)-oxide derivative (23)

To a solution of **6** (2.8 mg) in $CHCl_3$ (0.3 mL) was added *m*-CPBA (1.0 mg) in $CHCl_3$ (300 μL) and the mixture was kept at 4 °C for 10 min. After evaporation, the residue was applied to a silica gel column ($CHCl_3$/MeOH, 9:1) to give **23** (1.0 mg, 34.8 %): $[\alpha]_D^{27}$ −14 (*c* 0.5, MeOH); IR (film) 1740 and 1710 $cm^{-1}$; $^1H$ NMR ($CD_3OD$) δ 7.24 (dd, 8.5, 2.0, H-5′), 7.11 (d, 2.0, H-2′), 7.03 (d, 2.6, H-9), 6.93 (d, 8.5, H-5′), 6.56 (d, 8.6, H-12), 6.40 (dd, 8.6, 2.6, H-11), 5.69 (q, 6.7, H-19), 5.05 (br s, H-5), 4.81 (d, 11.1, H-17), 4.34 (d, 16.4, H-21) 4.16 (d, 16.4, H-21), 4.03 (d, 3.2, H-3), 3.89 (s, –OMe), 3.88 (s, –OMe), 3.74 (s, –OMe), 3.60 (br s, H-15), 3.34 (s, –OMe), 3.30 (m, H-6), 2.95 (s, –NMe), 2.50 (m, H-6), 2.47 (m, H-14), 2.25 (d, 15.8, H-14), 1.72 (dd, 6.7, 2.3, H-18); HRESIMS *m*/*z* 593.2522 [calcd for $C_{32}H_{37}N_2O_9(M+H)^+$, 593.2499].

### 3.3.10. Conversion of 7 to its *N*(4)-oxide derivative (24)

To a solution of **7** (1.0 mg) in $CHCl_3$ was added *m*-CPBA (1.6 mg) in $CHCl_3$ (300 μL) and the mixture was kept at 4 °C for 10 min. After evaporation, the residue was applied to a silica gel column ($CHCl_3$/MeOH, 9:1) to give **24** (1.0 mg, 34.8 %): $[\alpha]_D^{27}$ −24 (*c* 0.5, MeOH)); IR (film) 1730 and 1720 $cm^{-1}$; $^1H$ NMR ($CDCl_3$) δ 7.08 (d, 2.6, H-12), 6.89 (s, H-2′, 5′), 6.52 (d, 8.6, H-9), 6.52 (d, 8.6, H-9), 6.52 (d, 8.6, H-12), 6.36 (dd, 8.6, 2.6, H-11), 5.64 (q, 7.12, H-19), 5.21 (br s, 3.54, H-5), 4.80 (d, 10.9, H-17), 4.44 (d, 16.7, H-21) 4.32 (d, 16.7, H-21), 4.19, (d, 2.4, H-3), 4.06 (d, 10.9, H-17), 3.91 (s, –OMe), 3.88 (s, –OMe), 3.72 (s, –OMe), 3.45 (br s, H-15), 3.34 (s, –OMe), 3.30 (m, H-6), 3.00 (s, –NMe), 2.58 (dd, 15.6, 3.5, H-6), 2.54 (d, 15.7, H-14), 2.20 (d, 15.7, H-14), 1.69 (dd, 7.0, 2.0, H-18); HRESIMS *m*/*z* 623.2624 [calcd for $C_{33}H_{39}N_2O_{10}(M+H)^+$, 623.2605].

### 3.3.11. Conversion of 3 to its cinnamoyl derivative (25)

Compound **3** (13.9 mg), hydrocinnamic acid (5.8 mg), and DMAP (5.7 mg), were combined with $CH_2Cl_2$ (100 μL). 1,3-Dicyclohexylcarbodiimide (DCC) (23.5 mg) in $CH_2Cl_2$ (50 μL) was added dropwise over 10 min at 0 °C. The solution was warmed to room temperature and stirred overnight. The reaction mixture was partitioned with $CHCl_3$ and 1 N aq HCl, 10 % aq $NaHCO_3$, and water. The combined organic extract was dried ($Na_2SO_4$) and concentrated in vacuo and then purified by an ODS HPLC (MeOH/$H_2O$/formic acid, 60:40:0.1; flow rate, 2 mL/min; UV detection at 254 nm) to obtain compound **25** (0.7 mg, 3.8%): $[\alpha]_D^{27}$ −49 (*c* 0.5, MeOH); IR (film) 1740 and 1710 $cm^{-1}$; $^1H$ NMR ($CD_3OD$) δ 7.52 (m, H-4′, 8′), 7.41 (m, H-5′, 6′, 7′), 7.24 (d, 16.1, H-2′), 7.08 (s, H-9), 6.58 (s, H-11, 12), 5.97 (d, 16.1, H-1′), 5.52 (q, 7.4, H-19), 4.98 (m, H-5), 4.65 (d, 10.9, H-17), 4.08 (d, 10.9, H-17), 3.83 (m, H-21), 3.79 (m, H-3), 3.71 (s, –OMe), 3.68 (m, H-21), 3.48 (s, –OMe), 3.48 (m, H-15), 3.30 (m, H-6), 2.90 (s, –NMe), 2.39 (d, 14.6, H-6), 2.12 (d, 14.3, H-14), 2.04 (d, 14.3, H-14), 1.65 (d, 7.4, H-18); HRESIMS *m*/*z* 543.2490 [calcd for $C_{32}H_{35}N_2O_6(M+H)^+$, 543.2495].

### 3.3.12. Conversion of 3 to its acetylate derivative (26)

Compound **3** (1.0 mg), acetic anhydride (7.5 μL), triethylamine (2.5 μL), and DMAP (0.5 mg) in $CH_2Cl_2$ (50 μL) was stirred at room temperature for 1.5 h. The reaction mixture was partitioned with $CHCl_3$ and 10 % aq $NaHCO_3$. The combined organic extract was concentrated in vacuo and then purified by a silica gel column ($CHCl_3$/MeOH, 1:0–0:1) to obtain compound **26** (0.8 mg, 73.4%). $[\alpha]_D^{27}$ −32 (*c* 0.5, MeOH); IR (film) 1740 $cm^{-1}$; $^1H$ NMR ($CD_3OD$) δ 7.02 (d, 2.6, H-12), 6.73 (dd, 8.6, 2.6, H-11), 6.61 (d, 8.6, H-9), 5.51 (q, 7.3, H-19), 4.94 (m, H-5) 4.53 (d, 11.0, H-17), 3.86, (d, 11.0, H-17), 3.78 (d, 14.6, H-21), 3.72 (s, –OMe), 3.70 (s, –OMe), 3.44 (br s, H-3), 3.36 (m, H-21), 3.35 (m, H-15), 3.30 (m, H-6), 2.89 (s, –NMe), 2.36 (dd, 14.4, 2.8, H-6), 2.09 (d, 15.4, H-14), 2.00 (d, 15.4, H-14), 1.64 (d, 7.3, H-18), 1.54 (s, $-COCH_3$); HRESIMS *m*/*z* 455.2161 [calcd for $C_{25}H_{31}N_2O_6(M+H)^+$, 455.2182].

### 3.3.13. Conversion of 3 to its propionate derivative (27)

To a solution of **3** (1.6 mg) in $CH_2Cl_2$ (0.05 mL) was added propionic anhydride (3 μL), and DMAP (1.2 mg) in $CH_2Cl_2$ (50 μL) and the solution was stirred at room temperature. The mixture was diluted with $CHCl_3$ and washed with water, satd aq $NaHCO_3$, and water. The organic phase was dried over $MgSO_4$ and concentrated in vacuo and then purified by an ODS HPLC (MeOH/$H_2O$/formic acid; flow rate, 2 mL/min; UV detection at 254 nm) to obtain **27** (0.2 mg, 60.0%). $[\alpha]_D^{27}$ −143 (*c* 0.1, MeOH); IR (film) 1740 $cm^{-1}$; $^1H$ NMR ($CD_3OD$) δ 7.02 (d, 2.6, H-2), 6.80 (dd, 8.6, 2.6, H-11), 6.70 (d, 8.6, H-12), 5.74 (q, 6.5, H-19), 5.55 (br s, H-5) 4.52 (d, 11.2, H-17), 4.21 (m, H-21), 3.98 (m, H-21), 3.93, (d, 11.2, H-17), 3.75 (m, H-3), 3.74 (s, –OMe), 3.73 (s, –OMe), 3.64 (br s, H-15), 3.23 (d, 15.5, H-6), 2.95 (s, –NMe), 2.61 (d, 15.5, H-6), 2.32 (d, 14.6, H-14), 2.21 (d, 14.6, H-14), 1.84 (m, H-1′), 1.72 (d, 6.5, H-18), 0.85 (t, 7.5, H-2′); HRESIMS *m*/*z* 469.2352 [calcd for $C_{26}H_{33}N_2O_6(M+H)^+$, 469.2339].

### 3.3.14. Conversion of 3 to its benzyl ether derivative (28)

To a solution of **3** (2.7 mg) in dry $CH_2Cl_2$ (53 μL) were added triethylamine (1.27 μL), benzyl bromide (0.93 μL), and DMAP (0.4 mg). The reaction mixture was heated for 3 h, then cooled to room temperature and diluted with $CHCl_3$. The organic phase was washed twice with an aqueous solution of $NaHCO_3$ and once with water. The organic phase was dried $Na_2SO_4$ and concentrated in vacuo. The residue was chromatographed on an ODS HPLC (MeOH/$H_2O$/formic acid, 61:39:0.1; flow rate, 2 mL/min; UV detection at 254 nm) to give **28** (0.6 mg, 18.2%): $[\alpha]_D^{27}$ −4.6 (*c* 0.5, MeOH); IR (film) 1730 $cm^{-1}$; $^1H$ NMR ($CD_3OD$) δ 7.64 (d, 7.8, H-3′, 7′), 7.57 (m, H-4′, 5′, 6′), 6.85 (m, H-9, 12), 6.78 (d, 9.5, H-11), 5.65 (m, H-5), 5.62 (m, H-19), 4.61 (s, H-1′), 4.45 (d, 16.1, H-21), 4.41 (s, H-3), 3.97 (d, 16.1, H-21), 3.77, (m, H-15) , 3.74 (s, –OMe), 3.72 (s, –OMe), 3.66 (d, 17.5, H-17), 3.61 (d, 17.5, H-17), 3.30 (m, H-6), 3.03 (s, –NMe), 2.54 (dd, 16.6, 3.7, H-6), 2.38 (m, H-14), 1.65 (d, 5.5, H-18); HRESIMS 503.2535 [calcd for $C_{30}H_{35}N_2O_5(M+H)^+$, 503.2546].

### 3.3.15. Uptake of Methyl-α-D-glucopyranoside in cultured cells expressing SGLT1 or SGLT2[18]

COS-1 cells were cultured at 37 °C in Dulbecco's modified Eagle's/Ham's F-12 medium (1:1) supplemented with 10% fetal calf serum. For the uptake assay, the cells were plated at $1 \times 10^5$ cells/24-well plate (Asahi Techno Glass, Tokyo, Japan), and 1 μg of each transporter plasmid was transfected into subconfluent cultures of COS-1 cells using Lipofectamine 2000 (Invitrogen). The cells were used 2–3 days after transfection. They were incubated in a pretreatment buffer [140 mM NaCl, 2 mM KCl, 1 mM $CaCl_2$, 1 mM $MgCl_2$, and 10 mM Hepes/Tris (pH 7.5)] with a test sample at 37 °C for 30 min. An uptake solution containing 80 mM methyl-α-D-glucopyranoside and 4 μCi/mL methyl α-D-[U-$^{14}$C]glucopyranoside was then added into each well and the mixture was incubated at 37 °C for 30 min. Following incubation, the plates were washed three times with cold stop buffer [140 mM choline chloride, 2 mM KCl, 1 mM $CaCl_2$, 1 mM $MgCl_2$, and 10 mM Hepes/Tris (pH 7.5)] containing 300 μM phlorizin. The cells were then solubilized with 0.1 M NaOH, and their radioactivity was measured with a liquid scintillation counter (3100TR, Perkin–Elmer). Phlorizine was used as a standard drug for this bioassay and its $IC_{50}$ values were 0.2 and 0.1 mM against SGLT1 and SGLT2, respectively.

## Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and a grant from The Open Research Center Project in Hoshi University.

## References and notes

1. Lee, W.-S.; Kanai, Y.; Wells, R. G.; Hediger, M. A. *J. Biol. Chem.* **1994**, *269*, 12032–12039.
2. You, G.; Lee, W.-S.; Barros, E. J. G.; Kanai, Y.; Huo, T.-L.; Khawaja, S.; Wells, R. G.; Nigam, S. K.; Heidiger, M. A. *J. Biol. Chem.* **1995**, *270*, 29365–29371.
3. Mackenzie, B.; Panayotova-Heiermann, M.; Loo, D. D. F.; Lever, J. E.; Wright, E. M. *J. Biol. Chem.* **1994**, *269*, 22488–22491.
4. Wright, E. M.; Turk, E. *Pfugers Arch.* **2004**, *447*, 510–518.
5. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hitatochi, M.; Itho, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. *J. Pharm. Exp. Ther.* **2007**, *320*, 323–330.
6. Morita, H.; Deguchi, J.; Motegi, Y.; Sato, S.; Aoyama, C.; Takeo, J.; Shiro, M.; Hirasawa, Y. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1070–1074.
7. (a) Kamarajan, P.; Sekar, N.; Mathuram, V.; Govindasamy, S. *Biochem. Int.* **1991**, *25*, 491–498; (b) Saraswathi, V.; Subramanian, S.; Ramamoorth, N.; Mathuram, V.; Govindasamy, S. *Med. Sci. Res.* **1997**, *25*, 167–170; (c) Keawpradub, N.; Kirby, G. C.; Steele, J. C. P.; Houghton, P. J. *Planta Med.* **1999**, *65*, 690–694; (d) Husain, K.; Jantan, I.; Kamaruddin, N.; Said, I. M.; Aimi, N.; Takayama, H. *Phytochemistry* **2001**, *57*, 603–606; (e) Husain, K.; Jantan, I.; Said, I. M.; Aimi, N.; Takayama, H. *J. Asian Nat. Prod. Res.* **2003**, *5*, 63–67; (f) Jagetia, G. C.; Baliga, M. S. *Phytother. Res.* **2006**, *20*, 103–109; (g) Khan, M. R.; Omoloso, A. D.; Kihara, M. *Fitoterapia* **2003**, *74*, 736–740; (h) Gupta, R. S.; Bhatnager, A. K.; Joshi, Y. C.; Sharma, M. C.; Khushalani, V.; Kachhawa, J. B. *Pharmacology* **2005**, *75*, 57–62.
8. Koyama, K.; Hirasawa, Y.; Zaima, K.; Hoe, T. C.; Chan, K.-L.; Morita, H. *Bioorg. Med. Chem.* **2008**, *16*, 6483–6488.
9. Hirasawa, Y.; Arai, H.; Zaima, K.; Oktarina, R.; Rahman, A.; Ekasari, W.; Indrayanto, G.; Zaini, N.; Morita, H. *J. Nat. Prod.* **2009**, *72*, 304–307.
10. Abe, F.; Yamauchi, T.; Shibuya, H.; Kitagawa, I.; Yamashita, M. *Chem. Pharm. Bull.* **1998**, *46*, 1235–1238.
11. Abe, F.; Chen, R.; Yamauchi, T.; Marubayashi, N.; Ueda, I. *Chem. Pharm. Bull.* **1989**, *37*, 887–890.
12. Mamatas-Kalamaras, S.; Sevenet, T.; Thal, C.; Potier, P. *Phytochemistry* **1968**, *7*, 2045–2051.
13. Burmel, R.; Medina, J. *Phytochemistry* **1968**, *7*, 2045–2051.
14. Caron, C.; Yachaoui, Y.; Massiot, G.; Men-Olivier, L.; Pusset, J.; Sevenet, T. *Phytochemistry* **1984**, *23*, 2355–2357.
15. Ratnayake, C.; Arambewela, L.; Silva, K.; Rahman, A.; Alvi, K. *Phytochemistry* **1975**, *14*, 1849–1854.
16. Abe, F.; Yamauchi, T.; Santisuk, T. *Phytochemistry* **1994**, *37*, 249–252.
17. Kam, T.; Choo, Y. *J. Nat. Prod.* **2004**, *67*, 547–552.
18. Sato, S.; Aoyama, C.; Takeo, J. *Bioorg. Med. Chem.* **2007**, *15*, 3445–3449.

Source details

Feedback > Compare sources >

Bioorganic and Medicinal Chemistry

Scopus coverage years: from 1993 to Present

Publisher: Elsevier

ISSN: 0968-0896 E-ISSN: 1464-3391

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science | Chemistry: Organic Chemistry | Biochemistry, Genetics and Molecular Biology: Clinical Biochemistry | Pharmacology, Toxicology and Pharmaceutics: Drug Discovery | View all

Source type: Journal

View all documents > | Set document alert | Save to source list | Source Homepage

CiteScore 2019
5.5

SJR 2019
0.739

SNIP 2019
0.940

# Bioorganic and Medicinal Chemistry

**COUNTRY**

United Kingdom

Universities and research institutions in United Kingdom

**SUBJECT AREA AND CATEGORY**

Biochemistry, Genetics and Molecular Biology
- Biochemistry
- Clinical Biochemistry
- Molecular Biology
- Molecular Medicine

Chemistry
- Organic Chemistry

Pharmacology, Toxicology and Pharmaceutics
- Drug Discovery
- Pharmaceutical Science

**PUBLISHER**

Elsevier Ltd.

**H-INDEX**

154

**PUBLICATION TYPE**

Journals

**ISSN**

14643391, 09680896

**COVERAGE**

1993-2020

**INFORMATION**

Homepage

How to publish in this journal

Contact

**SCOPE**

Bioorganic & Medicinal Chemistry publishes complete accounts of research of outstanding significance and timeliness on all aspects of molecular interactions at the interface of chemistry and biology, together with critical review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. The Journal welcomes papers on: the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targets- the reporting of the discovery, design or optimization of potent new compounds or biological agents- the analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental data- the reporting of "first-in-class" new therapeutic compounds- the chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanism- methodological advances that are chemistry-based and which significantly impact on medicine or biology- the preparation and examination of biotherapeutics for the treatment of pathophysiological disease states- the development of materials for specific therapeutic targeting


Quartiles
Biochemistry
Clinical Biochemistry
Drug Discovery
Molecular Biology
Molecular Medicine
Organic Chemistry
Pharmaceutical Science
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019


SJR
1.25
1
0.75
0.5
1999 2002 2005 2008 2011 2014 2017


Total Cites
Self-Cites
10k
5k
0
1999 2002 2005 2008 2011 2014 2017


Citations per document
3.6
3.2
2.8
2.4
2
1.6
1999 2002 2005 2008 2011 2014 2017
Cites / Doc. (4 years)
Cites / Doc. (3 years)
Cites / Doc. (2 years)


External Cites per Doc
Cites per Doc
4
3
2
1
1999 2002 2005 2008 2011 2014 2017


% International Collaboration
35
28
21
14
1999 2002 2005 2008 2011 2014 2017


Citable documents
Non-citable documents
4k
2k
0
1999 2002 2005 2008 2011 2014 2017


Cited documents
Uncited documents
4k
2k
0
1999 2002 2005 2008 2011 2014 2017


Bioorganic and Medicinal Chemistry
Q1
Pharmaceutical Science
SJR 2019
0.74
powered by scimagojr.com
← Show this widget in your own website
Just copy the code below and paste within your html code:
<a href="https://www.sc